Zur Rose AG

EQS-News: Extraordinary General Meeting of Zur Rose Group AG: Shareholders approve creation of authorised capital and revision to Articles of Association for initial public offering (IPO)


EQS Group-News: Zur Rose Group AG / Key word(s): AGM/EGM
Extraordinary General Meeting of Zur Rose Group AG: Shareholders approve
creation of authorised capital and revision to Articles of Association for
initial public offering (IPO)

19.06.2017 / 19:08
--------------------------------------------------------------------------------
Media release

Extraordinary General Meeting of Zur Rose Group AG:

Shareholders approve creation of authorised capital and revision to Articles of
Association for initial public offering (IPO)

At today's Extraordinary General Meeting, the shareholders of Zur Rose Group AG
approved all proposals from the Board of Directors by a large majority. A total
of 2,436,167 voting shares, equal to 51.1 per cent of the share capital, were
represented. The General Meeting approved the formal amendments to the Articles
of Association necessary for a stock exchange listing: the creation of
authorised share capital with a nominal value of CHF 12,474,159.25,
corresponding to 5 per cent of the existing share capital (2,169,419 registered
shares with a nominal value of CHF 5.75 each), as well as the complete revision
of the Articles of Association required for an IPO. The revised Articles of
Association will become effective only upon completion of the capital increase
as part of an IPO of Zur Rose Group AG. The IPO would take place on SIX Swiss
Exchange. Among other things, Zur Rose Group would use the funds raised in the
capital increase to better exploit the growth opportunities in the market to
further expand its strong position in the European pharmaceutical e-commerce
sector.

Contact

Lisa Lüthi, Head of Corporate Communications
Email: lisa.luethi@zurrose.com, telephone: +41 52 724 08 14

Zur Rose Group

Operating under the "Zur Rose" and "DocMorris" brands, the Swiss-based Zur Rose
Group is Europe's leading online pharmacy and one of Switzerland's foremost
wholesale suppliers to medical practitioners. Through its business model, it
helps to ensure safe, reliable and high-quality pharmaceutical care, while also
excelling in developing innovative medicines management services to increase the
effectiveness of the medication process. This creation of added value, the
strong focus on patients and the commitment to supply pharmaceuticals at low
cost make the Group an important strategic partner for healthcare providers,
payers and industry.

The Zur Rose Group is headquartered in Frauenfeld, from where it is also serves
the Swiss market. In Germany and Austria, the Group operates through
subsidiaries in Heerlen (Netherlands) and Halle an der Saale (Germany).
Furthermore, it holds a majority interest in BlueCare in Winterthur, the leading
provider of networking systems in the Swiss healthcare market. Employing more
than 800 people at its various locations, the Zur Rose Group generated revenue
of CHF 880 million in 2016.

Zur Rose Group AG's shares (Swiss security no. 4261528, ISIN CH0042615283) are
traded on the Berner Kantonalbank's OTC-X, Zürcher Kantonalbank's eKMU-X and
Lienhardt & Partners Private Bank Zurich Ltd's trading platforms. The CHF 50
million corporate bond issued in November 2012 for the purpose of financing the
DocMorris acquisition is listed on the SIX Swiss Exchange (Swiss security no.
19972936, ISIN CH0199729366, ticker symbol ZRO12). zurrosegroup.com

Disclaimer

This communication may contain statements about the future that use words such
as, for example, "believe", "assume", "expect" and other similar expressions.
Such statements about the future are subject to risks, uncertainties, and other
factors, which can cause the true results of the company to differ significantly
from that which is expressly or implicitly assumed in these statements. In view
of these uncertainties, the reader should not depend on this type of statement
about the future. The company gives no undertaking whatever to update such
statements regarding the future, or to adapt them to future events or
developments.

--------------------------------------------------------------------------------
End of Corporate News
--------------------------------------------------------------------------------

Language: English

Company:  Zur Rose Group AG

          Walzmühlestrasse 60

          8500 Frauenfeld

          Switzerland

Phone:    +41 52 724 08 14

Internet: www.zurrosegroup.com

ISIN:     CH0199729366, CH0042615283

Listed:   SIX Swiss Exchange



 

End of News EQS Group News Service

--------------------------------------------------------------------------------

584325  19.06.2017 
 



Weitere Meldungen: Zur Rose AG

Das könnte Sie auch interessieren: